Article
A tumor metabolism-angiogenesis-immune axis governs immunotherapy responses
2026-02-24
Abstract excerpt
Despite the clinical success of immunotherapy, long-lasting benefit remains restricted to a subset of patients. Tumor metabolic adaptation is emerging as a key factor limiting immunotherapy efficacy. We previously found that glycolysis-low tumor variants, compared to the parental glycolytic tumors, better respond to neoadjuvant CTLA-4 immune checkpoint blockade (ICB) therapy. Here, we investigated new rational mod...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9dea7c5e-e0a3-5c45-8bf5-deb09abcc3fd
- DOI
- 10.64898/2026.02.23.707524
